EMA Authorised: Efmody (hydrocortisone) — Immedica Pharma AB

View source ↗

Summary

Efmody (hydrocortisone) by Immedica Pharma AB has been authorised for congenital adrenal hyperplasia in the EU.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Congenital Adrenal Hyperplasia

Drugs mentioned

• Efmody (hydrocortisone)

Snippet

Status: Authorised. Therapeutic area: Adrenal Hyperplasia, Congenital. MAH: Immedica Pharma AB. Decision date: 11/05/2026